NCT02575482View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

June 30, 2016

Conditions

Cognitive Disorders

Interventions

DRUG

SUVN-D4010

DRUG

Placebo

Trial Locations (1)

66219

PRA Health Sciences, Lenexa

All Listed Sponsors

lead

Suven Life Sciences Limited

INDUSTRY

NCT02575482 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects | Biotech Hunter | Biotech Hunter